Antibody therapy in steroid-resistant rejection.
Waiser
J
J
Department of Internal Medicine-Nephrology, Charité, Humboldt-University, Berlin, Germany.
Budde
K
K
Schreiber
M
M
Böhler
T
T
Löbermann
L A
LA
Neumayer
H H
HH
D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D004351:Drug Resistance; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine